Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Post by riskreward1111on May 31, 2017 1:25pm
118 Views
Post# 26306811

The Best ?

The Best ?

MF...Want to Invest in Marijuana Stocks?

Aphria is already profitable

Unlike Canopy and Aurora Cannabis, Aphria is already profitable. The company reported its fifth quarterly profits in April, growing its Q3 earnings before interest, tax, depreciation, and amortization (EBITDA) by a whopping 137% to a little more than $1 million as sales jumped twofold. During the trailing 12 months, Aphria earned nearly $8 million in net income compared to Canopy and Aurora, which lost roughly $1 million and $16 million, respectively, during the period.

When you’re investing in a disruptive industry, there’s nothing better than putting your money into a company already making money.

Aphria is growing rapidly

One thing I like about Aphria and that gives me confidence in the company’s management is its focus on organic growth, unlike peers like Canopy, which are largely pursuing growth via acquisitions.

After completing its Part III expansion phase by September this year, Aphria’s Phase IV expansion, projected to complete by July 2018, will more than triple its greenhouse capacity to one million square feet and lower its costs by $5-50 per square foot. Its production capacity will jump to 75,000 kg from under 20,000 kg currently.

For an industry moving to legalize recreational cannabis and staring at a boom, Aphria’s organic-growth moves are a step in the right direction.

Aphria has strong financials

Aphria is expanding rapidly, but it has no debt on its books and even generated positive operating cash flow while holding $16 million in cash and cash equivalents during the trailing 12 months. Its phase IV expansion program is also already fully funded.

In short, Aphria has pretty strong financials and is already making money, unlike most marijuana players. Aphria also has among the lowest production costs per gram, which is a huge competitive advantage. Aphria is already poised to benefit hugely if Canada legalizes recreational marijuana while it expands its footprint in the U.S. I wouldn’t be surprised to see Aphria’s bottom line expand rapidly in coming years, which could push its stock price even higher as growing profits support valuations.

Bullboard Posts